Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.15−0.39 (-4.57%)
Close on Nov 17, 2026Market cap $284.29MP/E –Yield –
Benitec Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Benitec Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$51.19M. For fiscal 2026 it was -$51.19M. The highest annual figure on record is $2.58M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$51.19M | – |
| FY2025 | Jun 30, 2025 | -$41.77M | – |
| FY2024 | Jun 30, 2024 | -$22.49M | – |
| FY2023 | Jun 30, 2023 | -$19.08M | – |
| FY2022 | Jun 30, 2022 | -$17.85M | – |
| FY2021 | Jun 30, 2021 | -$13.60M | – |
| FY2020 | Jun 30, 2020 | -$8.28M | -420.6% |
| FY2019 | Jun 30, 2019 | $2.58M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$14.43M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$13.58M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$13.38M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$9.80M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$9.83M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$15.34M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$10.81M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$5.79M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$5.55M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$4.14M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$6.93M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$5.87M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$4.55M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$4.34M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$5.61M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$4.58M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$4.74M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.46M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$4.84M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$4.82M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$3.86M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.79M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$3.26M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$2.69M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$2.89M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$2.11M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$2.11M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$1.17M | – |
See a number that looks wrong?